Breaking Down the CVOTs

Slides:



Advertisements
Similar presentations
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Advertisements

Diabetic Dyslipidemia in Practice
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
New Data on the Safety of SGLT2 Inhibitors
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Updates on CVOT Data and Clinical Comparisons That Matter
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
What Comes Second?.
Insulin Innovation.
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
SGLT2 Inhibitors and CV Outcomes
Emerging CVOT Data and Clinical Application
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Impacting CV Risk With Diabetes Medications
EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.
Impacting CV Risk With Diabetes Medications
Clinical Application of New CV Outcomes Data
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
PCSK9 Inhibitors and Cardiovascular Outcomes
Tackling CV Risk in T2DM.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Early and Intensive T2D Management:
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.
The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia.
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Learning Objectives Metabolic Abnormalities Associated With T2D.
Antihyperglycemic Therapy
CV Outcomes and Adherence With GLP-1 RAs
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Oral Combination Therapy for T2D
Updates From ACC.
Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Overall Health
DECLARE-TIMI 58.
2015 EASD In Review: CV Risk management in t2dm
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Glucose-lowering medication in type 2 diabetes: overall approach.
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
The Power of As-Treated Analyses
In the Know.
Presentation transcript:

Breaking Down the CVOTs

Why CVOTs and What Do They Mean?

Increased Risk of Mortality and CVD in T2D

Completed and Ongoing CVOTs Study Populations

Published CVOTs Different Populations

Published DPP-4 Inhibitor CVOTs Comparison of Results

GLP-1 RA CVOTs Comparison of Results

SGLT2 Inhibitor CVOT Results From EMPA-REG OUTCOME

CANVAS Study Population

EMPA-REG OUTCOME and CANVAS CVOTs Comparison of Results

CANVAS Canagliflozin Is Renoprotective

Implications for Clinical Practice RCTs vs Real World

CANVAS: Safety of Canagliflozin

Closing Comments

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.